Related Experiment Video

Updated: May 28, 2026

A High Output Method to Isolate Cerebral Pericytes from Mouse
06:49

A High Output Method to Isolate Cerebral Pericytes from Mouse

Published on: January 14, 2020

Pericyst may be a new pharmacological and therapeutic target for hydatid disease

Xiang-Wei Wu1, Xue-Ling Chen, Shi-Jie Zhang

  • 1Department of Hepatobiliary Surgery, School of Medicine, Shihezi University, Shihezi, Xinjiang 832000, China.

Chinese Medical Journal
|November 2, 2011
PubMed
Abstract

Insights

Inhibition of transforming growth factor-beta 1 (TGF-β1) signaling promotes hydatid cyst calcification. This finding suggests targeting TGF-β1 may offer a new therapeutic strategy for hydatid disease.

Area of Science:

  • Parasitology
  • Cell Biology
  • Biochemistry

Background:

  • Hydatid cysts with calcified walls are typically inactive.
  • Transforming growth factor-beta 1 (TGF-β1) is crucial in cellular calcification.
  • This study investigates TGF-β1's role in hydatid cyst calcification.

Purpose of the Study:

  • To assess the impact of modulating TGF-β1 signaling on hydatid cyst calcification.
  • To explore potential therapeutic targets for hydatid disease.

Main Methods:

  • Cultured pericyst cells from hepatic hydatid cysts with osteogenic media.
  • Analyzed alkaline phosphatase activity and mineralization (Alizarin Red staining).
  • Investigated effects of TGF-β1 and its inhibitor on osteoblast marker expression (Western blotting) and pericyst wall calcification in an animal model.

Main Results:

  • Pericyst cells exhibited osteoblast-like activity and mineralization.
  • TGF-β1 inhibited these activities, while TGF-β1 inhibitor enhanced them.
  • Inhibition of TGF-β1 signaling in vivo increased pericyst calcification, reduced cyst load, and decreased protoscolex viability.

Conclusions:

  • Pericyst cells possess osteogenic potential and adopt an osteoblast-like phenotype.
  • Inhibiting TGF-β1 signaling enhances hydatid cyst calcification.
  • Pharmacological targeting of pericyst calcification presents a novel therapeutic avenue for hydatid disease.

More Related Videos

3D Visualization of Retinal Vascular Pericytes in Mice by Immunostaining09:22

3D Visualization of Retinal Vascular Pericytes in Mice by Immunostaining

Published on: November 1, 2024

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...